EGFR and glioblastoma: Genomic and transcriptomic analysis of anti-EGFR CAR T cell-treated glioblastoma cells showed an upregulation of genes for inhibitory immune checkpoints, inflammatory cytokines, and immunosuppressive molecules, limiting CAR T cell efficacy [111].